Contract research organisation hVIVO plc (AIM:HVO) announced on Monday that it has signed an agreement with clinical-stage biotechnology company Inhalon Biopharma Inc to conduct a Respiratory Syncytial Virus (RSV) human challenge trial.
The Phase 2a trial will assess Inhalon's inhaled antiviral candidate, IN-002, using hVIVO's RSV Human Challenge Model. It will evaluate IN-002's safety, pharmacokinetics and antiviral activity at three dose levels.
hVIVO's FluCamp will recruit healthy volunteers for the study. The trial is expected to begin in the second half of 2026 at hVIVO's Canary Wharf facilities.
Revenue from the contract is primarily expected to be recognised in 2026.
IN-002 uses Inhalon's inhaled drug delivery platform.
Roivant to announce Q3 2026 financial results
Avacta secures FDA clearance for second pre|CISION oncology programme
OncoHost receives BIG Innovation Award in Health category
Summit Therapeutics and GSK form collaboration to study ivonescimab combination therapy
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Antin to acquire clinical trial equipment provider Emsere
Merck completes acquisition of Cidara Therapeutics for USD9.2bn
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
Kelun-Biotech lung cancer drug granted Breakthrough Therapy Designation in China
INOVIO's INO-3107 Biologics License Application accepted by US FDA
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA